Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children

Moxifloxacin is a recommended drug for rifampin-resistant tuberculosis (RR-TB) treatment, but there is limited pediatric pharmacokinetic and safety data, especially in young children. We characterize moxifloxacin population pharmacokinetics and QT interval prolongation and evaluate optimal dosing in...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Clinical infectious diseases Ročník 74; číslo 8; s. 1372
Hlavní autori:	Radtke, Kendra K, Hesseling, Anneke C, Winckler, J L, Draper, Heather R, Solans, Belen P, Thee, Stephanie, Wiesner, Lubbe, van der Laan, Louvina E, Fourie, Barend, Nielsen, James, Schaaf, H Simon, Savic, Radojka M, Garcia-Prats, Anthony J
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 28.04.2022
Predmet:	Adult Child Child, Preschool Electrocardiography Fluoroquinolones - adverse effects HIV Infections Humans Moxifloxacin - adverse effects Rifampin - adverse effects Rifampin - pharmacokinetics Tuberculosis - drug therapy Tuberculosis, Multidrug-Resistant - drug therapy pharmacokinetics pediatrics tuberculosis moxifloxacin
ISSN:	1537-6591, 1537-6591
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!